Prolgolimab for advanced facial melanoma (a clinical case description and a brief literature review)
Melanoma of the skin can certainly be attributed to the group of aggressive malignant neoplasms, which are characterized by high mortality and frequent relapses. However, in recent years, there have been revolutionary changes in the treatment of melanoma. The introduction of targeted and immunotherapy into clinical practice has significantly changed the unfavorable prognosis and thus increased the life expectancy of patients. This article presents a clinical case of the successful use of the domestic immuno-oncological drug prolgolimab in a patient with advanced facial melanoma of the older age group. Also, a brief description of key clinical studies devoted to the study of domestic monoclonal antibodies in skin melanoma is given.
Authors
- Evgenia Kuzmina (ORCID: https://orcid.org/0009-0007-2856-5176)
- S.A. Golubeva (ORCID: https://orcid.org/0000-0002-0633-1738)
- P. V. Golubev (ORCID: https://orcid.org/0000-0003-3532-6476)
- Vladislav Kuzmin (ORCID: https://orcid.org/0009-0000-9658-3586)
- L. I. Barskaya (ORCID: https://orcid.org/0009-0004-8626-6340)
Institutions
- Sechenov University (RU)
- Ministry of Health of the Russian Federation (RU)
- Medical Radiological Research Center (RU)
- City Clinical Hospital (RU)
- P.A. Hertzen Moscow Oncology Research Institute (RU)
Publication Details
- Journal
- Head and neck tumors (HNT)
- Published
- 2026-11-20
- DOI
- https://doi.org/10.17650/2222-1468-2026-16-3-105-109
- Primary Topic
- Cutaneous Melanoma Detection and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00